Peptipedia
ImmuneIn Clinical TrialsClinical Trials

VIP

Also known as Vasoactive Intestinal Peptide, Aviptadil

A naturally occurring peptide exhibiting immunomodulatory and anti-inflammatory properties being investigated for ARDS, pulmonary hypertension, and autoimmune disorders.

Clinical Trials - Multiple indications
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

50-100 mcg intranasal daily

Frequency

1-2x daily

Duration

Variable by indication

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 50-100 mcg intranasal daily via IV infusion, inhaled, or intranasal, 1-2x daily. Dose range: 25-150 mcg daily. Duration: Variable by indication.

Timing & Administration

Administer via IV infusion, inhaled, or intranasal. Frequency: 1-2x daily.

Mechanism of Action

Binds to VPAC1 and VPAC2 receptors, triggering anti-inflammatory cascades. Relaxes smooth muscle, vasodilates, inhibits pro-inflammatory cytokines, and promotes regulatory T-cell function.

Research Summary

Evidence level: clinical trials. Clinical status: Clinical Trials - Multiple indications.

Side Effects & Safety

Important Warnings

  • Short-lived effects due to instability
Nausea and diarrhea
injection site reactions
headache
dizziness
facial flushing
blood pressure decrease

References

No references available.

Related Peptides

Browse all →
LL-37Immune

A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.

View profile
Thymosin Alpha-1Immune

A naturally occurring thymic peptide that enhances immune function.

View profile
KPVImmune

A tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.

View profile